Abstract:The ubiquitin-proteasome system (UPS) promotes the timely degradation of short-lived proteins with key regulatory roles in a vast array of biological processes, such as cell cycle progression, oncogenesis and genome integrity. Thus, abnormal regulation of UPS disrupts the protein homeostasis and causes many human diseases, particularly cancer. Indeed, the FDA approval of bortezomib, the first class of general proteasome inhibitor, for the treatment of multiple myeloma, demonstrated that the UPS can be an attractive anti-cancer target. However, normal cell toxicity associated with bortezomib, resulting from global inhibition of protein degradation, promotes the focus of drug discovery efforts on targeting enzymes upstream of the proteasome for better specificity. E3 ubiquitin ligases, particularly those known to be activated in human cancer, become an attractive choice. Cullin-RING Ligases (CRLs) with multiple components are the largest family of E3 ubiquitin ligases and are responsible for ubiquitination of similar to 20% of cellular proteins degraded through UPS. Activity of CRLs is dynamically regulated and requires the RING component and cullin neddylation. In this review, we will introduce the UPS and CRL E3s and discuss the biological processes regulated by each of eight CRLs through substrate degradation. We will further discuss how cullin neddylation controls CRL activity, and how CRLs are being validated as the attractive cancer targets by abrogating the RING component through genetic means and by inhibiting cullin neddylation via MLN4924, a small molecule indirect inhibitor of CRLs, currently in several Phase I clinical trials. Finally, we will discuss current efforts and future perspectives on the development of additional inhibitors of CRLs by targeting E2 and/or E3 of cullin neddylation and CRL-mediated ubiquitination as potential anti-cancer agents.

The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies

CBLN2 Overexpression Inhibits Colorectal Cancer Progression and Improves Immunotherapy Responses

The emerging role for Cullin 4 family of E3 ligases in tumorigenesis

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases

Targeting SCF E3 Ligases for Cancer Therapies

E3 Ligase C-Cbl Mediates Ubiquitination-Proteasomal Degradation Of Bcr-Abl And Therapeutic Effects Against Bcr-Abl Leukemia

CBL Family E3 Ubiquitin Ligases Control JAK2 Ubiquitination and Stability in Hematopoietic Stem Cells and Myeloid Malignancies

Targeting Cbl-b in cancer immunotherapy

Roles of Ubiquitination in the Crosstalk Between Tumors and the Tumor Microenvironment (Review)

Cullin-RING Ligases as attractive anti-cancer targets.

Targeting Cul3-scaffold E3 ligase complex <i>via</i> KLHL substrate adaptors for cancer therapy

CBLC promotes the development of colorectal cancer by promoting ABI1 degradation to activate the ERK signaling pathway

The Regulation of E3 Ubiquitin Ligases Cbl and its Cross-talking in Bone Homeostasis

E3 Ubiquitin Ligases in Cancer and Implications for Therapies

Mechanisms of Cbl-Mediated Ubiquitination of Proteins in T and Natural Killer Cells and Effects on Immune Cell Functions

Target deubiquitinase OTUB1 as a therapeatic strategy for BLCA via β-catenin/necroptosis signal pathway

Relationship of Ubiquitin-Ligases APC/C and SCF Complex to Cancer

Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors

Phosphorylation regulates cullin-based ubiquitination in tumorigenesis

Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications